Evolving Innovative Trial Design with Diverse Patient Populations to Optimize Clinical Development

Time: 11:00 am
day: Day 2 Stream 2 AM


  • Designing a robust development program to accelerate drug development
  • F1, F2, F3, F4: navigating diverse patient populations in clinical studies to optimize treatment
  • Evaluating clinical development of EFX in Phase IIb and histological outcomes